Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

KEK and Astellas Begin Collaborative Research to Discover New Drugs for Neglected Tropical Diseases

Published: Monday, October 08, 2012
Last Updated: Monday, October 08, 2012
Bookmark and Share
The design of the novel pharmaceuticals will be based on the three-dimensional structure of proteins using synchrotron X-ray crystallography.

The High Energy Accelerator Research Organization  (KEK) and Astellas Pharma Inc. will begin collaborative research to discover new drugs  for the  treatment of neglected tropical  diseases through the use of synchrotron X-ray crystallography. 

The target of this research is infectious diseases caused by parasitic protozoans, namely leishmaniasis, Chagas disease and Sleeping sickness and will be divided into two major phases. The first phase involves elucidating the three-dimensional structure of parasitic protozoan proteins that are potential drug targets, allowing the identification of inhibiting compounds that block the action of pathogenic proteins. The second phase consists of the Access to Healthstructural analysis of target proteins in complex with the inhibitory compound. Crystallization robots and dedicated beamlines developed by KEK will be employed with structural analysis performed efficiently and over a short time period.    Structural data obtained through the successful application of this collaborative research will contribute to the discovery of new drugs for the treatment of parasitic protozoan diseases.  

Neglected Tropical Diseases (NTDs), prevalent mainly in poor remote rural areas, are infectious diseases spread by parasites or bacteria. Approximately one billion people are affected worldwide and some 500,000 die each year as a result. NTDs are a serious healthcare issue that is being addressed on a global scale. A valuable approach to new drug development that has evolved rapidly in recent years is the design of pharmaceuticals based on the three-dimensional structure of proteins. This method involves designing drugs for the target protein by analyzing and comparing the structure of various compounds and complex conjugates in order to develop an overall understanding of the mechanism by which protein activity is inhibited (or activated). Since 2006, KEK and Astellas have been progressing drug discovery research using synchrotron X-ray beams. The synchrotron  radiation  beam produced in the Photon Factory in KEK  has high-brilliant and high-energy  properties conferring advantages such as the ability to  conduct  experiments on small  crystals that would have been difficult to analyze using conventional X-rays and to acquire data in an  extremely short period that would otherwise take vast amounts of time.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
Both Companies will exchange approximately 400,000 selected compounds.
Saturday, March 22, 2014
Astellas to Form Strategic Partnership with ClearPath to Build Vaccine Portfolio
In-license vaccine technology for respiratory syncytial virus (RSV) from Mymetics.
Tuesday, January 07, 2014
Astellas Pharma Inc. Is First Japanese Pharma Company to Join SAFE-BioPharma
SAFE-BioPharma Association is responsible for the ongoing development and implementation of the global SAFE-BioPharma® digital identity and signature standard.
Thursday, June 20, 2013
Amgen and Astellas Announce Japan Alliance
Companies embark on innovative joint venture to address unmet medical needs of patients in Japan.
Thursday, May 30, 2013
Astellas Pharma and BioFocus Sign Target Discovery Agreement
Collaboration agreement with Astellas focused on discovering novel targets in the field of CNS disorders.
Friday, May 13, 2011
Astellas Pharma Europe Appoints Ken Jones as President and CEO
Ken Jones succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc.
Tuesday, April 19, 2011
Astellas Begins Screening Another Target From Metabolex Gene Database
Initiation of screening against unique target triggers milestone payment to Metabolex.
Monday, September 18, 2006
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos